ClinicalTrials.gg
RecruitingNCT07690917Updated Oct 9, 2026

A Study of a New PET Scanner in People With Cancer

An observational study in Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer and Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 9, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center — 6 open to participants now, 11 under way, none of them phase 3. Head and Neck Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
9th of 14
90 · median 152
Started
2026
the only one that year
Observational
14 of 52
4 open now
Primary completion
2029-06
later than 10 of 10 live
Registered
52nd of 52
by date

Among the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 2026, is one of 14 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 52nd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

Read the detailed description

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

03

Conditions studied

  • Non Small Cell Lung Carcinoma NSCLC
  • Head and Neck Cancer
  • Prostate Cancer

Keywords

  • Whole body PET scanner
  • 26-227
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any MSKCC patients with histologically confirmed cancer, who will be scheduled to receive a planned PET-CT scan at the MSK main campus may be enrolled in this image evaluation and improvement study. Potential patients will be identified by a member of the patient's treatment team at MSKCC, who will introduce the study to them.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility Criteria for objective #1:

  • Patients with -confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
  • Patients who are undergoing a planned PET-CT scan at main campus of MSK.
  • Patients must be ≥ 18 years old

Eligibility Criteria for objective #2:

  • Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
  • Patients with prostate or head and neck cancer.
  • Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
  • Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
  • Patients must be ≥ 18 years old

Eligibility Criteria for objective #3:

  • Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
  • Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK.
  • Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
  • Patients must be ≥ 18 years old

Eligibility Criteria for objective #4:

  • Patients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer
  • Patients must be ≥ 18 years old

Exclusion criteria

Exclusion Criteria:

  • Patients who suffer from claustrophobia.
  • Women who are pregnant or breast-feeding.
  • Patients \< 18 years of age
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with lung, head and neck, and prostate cancer

    The only investigational aspect of this quality improvement protocol is the acquisition of additional PET/CT imaging data (e.g. breath-hold, dynamic, and/or delayed acquisition) in patients who are already scheduled to receive a PET/CT scan as part of standard of care or under an existing clinical trial.

    Diagnostic Test: Biograph Vision Quadra scanner · Diagnostic Test: PET/CT

Interventions

  • Diagnostic testBiograph Vision Quadra scanner

    new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner.

  • Diagnostic testPET/CT

    Scheduled PET/CT scan

06

What researchers measure

Primary outcomes

  1. image quality

    Detection of any new/additional lesions on the delayed scan will be recorded using standard clinical interpretation.

    Time frame: 3 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Consent Only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Monmouth (Consent Only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Bergen (Consent Only )
    Montvale, New Jersey 07645, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Suffolk-Commack (Consent Only)
    Commack, New York 11725, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Westchester (Consent Only)
    Harrison, New York 10604, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
  • Memorial Sloan Kettering Nassau (Consent Only)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Heiko Schoder, MD · Contact212-639-8001
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 36 months is below that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 8, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedEligibility Criteria for objective #4:
  • AddedPatients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer
  • AddedPatients must be ≥ 18 years old
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Eligibility 3 inclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedEligibility Criteria for objective #4:
    • AddedPatients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer
    • AddedPatients must be ≥ 18 years old
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07690917
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jun 30, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Heiko Schoder, MD
Contact
schoderh@mskcc.org
212-639-8001
John Humm, PhD
Contact
212-639-7367
Heiko Schoder, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion